Scinai Immunotherapeutics Faces Nasdaq Delisting Warning
Ticker: SCNI · Form: 6-K · Filed: May 28, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | May 28, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: listing-requirements, compliance, delisting-risk
TL;DR
Nasdaq says Scinai might get delisted, company has a hearing to fight it.
AI Summary
Scinai Immunotherapeutics Ltd. received a Nasdaq staff determination letter on May 24, 2024, indicating non-compliance with shareholders' equity listing requirements. The company is scheduled for a hearing to present a plan to regain compliance.
Why It Matters
This Nasdaq warning could impact the company's stock liquidity and investor confidence, potentially affecting its ability to raise capital.
Risk Assessment
Risk Level: medium — The company is at risk of delisting from Nasdaq if it cannot present a satisfactory plan to regain compliance with shareholders' equity requirements.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Filer of the report
- Nasdaq (company) — Stock exchange where the company is listed
- May 24, 2024 (date) — Date of the Nasdaq staff determination letter
FAQ
What specific Nasdaq listing requirement is Scinai Immunotherapeutics non-compliant with?
The filing states the non-compliance is regarding shareholders' equity listing requirements.
When did Scinai Immunotherapeutics receive the Nasdaq staff determination letter?
The company received the letter on May 24, 2024.
What is the purpose of the upcoming hearing for Scinai Immunotherapeutics?
The hearing is to present a plan for regaining compliance with Nasdaq's listing requirements.
What was Scinai Immunotherapeutics' former name?
The company's former name was BiondVax Pharmaceuticals Ltd.
Where is Scinai Immunotherapeutics' principal executive office located?
Its principal executive office is located in Jerusalem, Israel.
Filing Stats: 262 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-05-28 14:14:09
Filing Documents
- ea0206963-6k_scinai.htm (6-K) — 11KB
- ea020696301ex99-1_scinai.htm (EX-99.1) — 13KB
- 0001213900-24-046981.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: May 28, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2